Who
Vincent S. LoPriore
Executive Chairman
Company insider
Files Form 4 as: Executive Chairman, Hepion Pharmaceuticals; Executive Chairman, Canton Strategic Holdings.
In numbers
- Trades disclosed
- 17
- Buys
- 2
- Sells
- 0
- Bought
- $1.5M
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 3 Nov 2025
- Last trade
- 3 Sep 2026
- Last filed
- 14 Sep 2026
Companies traded
Activity over time
1 Apr – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Sep 2026filed 14 Sep 2026 | Hepion Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code P | —12,500,000 at $0.00 | filing |
| 3 Sep 2026filed 14 Sep 2026 | Hepion Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code P | —12,500,000 at $0.00 | filing |
| 19 Aug 2026filed 21 Aug 2026 | Hepion Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,345,500 at $0.00 | filing |
| 19 Aug 2026filed 21 Aug 2026 | Hepion Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,345,500 at $0.00 | filing |
| 3 Aug 2026filed 12 Aug 2026 | Hepion PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $400K8,000,000 at $0.05 | filing |
| 3 Aug 2026filed 12 Aug 2026 | Hepion PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $100K2,000,000 at $0.05 | filing |
| 3 Aug 2026filed 12 Aug 2026 | Hepion Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code P | —8,000,000 at $0.00 | filing |
| 3 Aug 2026filed 12 Aug 2026 | Hepion Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code P | —8,000,000 at $0.00 | filing |
| 3 Aug 2026filed 12 Aug 2026 | Hepion Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code P | —2,000,000 at $0.00 | filing |
| 3 Aug 2026filed 12 Aug 2026 | Hepion Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code P | —2,000,000 at $0.00 | filing |
| 3 Aug 2026filed 12 Aug 2026 | Hepion PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $400K8,000,000 at $0.05 | filing |
| 3 Aug 2026filed 12 Aug 2026 | Hepion PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $100K2,000,000 at $0.05 | filing |
| 21 Apr 2026filed 27 Apr 2026 | Hepion PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $200K5,000,000 at $0.04 | filing |
| 21 Apr 2026filed 27 Apr 2026 | Hepion PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $50K1,250,000 at $0.04 | filing |
| 21 Apr 2026filed 27 Apr 2026 | Hepion PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $200K5,000,000 at $0.04 | filing |
| 21 Apr 2026filed 27 Apr 2026 | Hepion PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $50K1,250,000 at $0.04 | filing |
| 3 Nov 2025filed 5 Nov 2025 | CNTN Canton Strategic Holdingsoption or derivative · Digital Asset Treasuries | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.